IN-DATE
1010020-SD: Bard Avitene Microfibrillar Collagen Hemostat Flour 1g
Sign in to add this product to your favorites!
| Price: | $169.99 EACH |
|---|---|
| Quantity: | |
| In Stock: | 7 eaches |
| Expiration: | 09-2026 |
Related Items
Additional Details
BD Bard Avitene™ Microfibrillar Collagen Hemostat Flour
Avitene™ Microfibrillar Collagen Hemostat is an active collagen hemostat, proven to help accelerate clot formation. Avitene™ effectively enhances platelet aggregation and the release of proteins to form fibrin, resulting in hemostasis.
Product Code: 1010020
- 1 gram
- Effective in controlling arterial bleeding
- Conforms and adheres to irregular spaces
- Easy removal with irrigation and suction
AccessGUDID Info
- FDA Product Code: LMF
- FDA Product Code Name: Agent, absorbable hemostatic, collagen based
- GMDN Term Code: 47201
- GMDN Term Name: Collagen haemostatic agent, non-antimicrobial
- GMDN Term Description: A bioabsorbable device derived from animal collagen (e.g., bovine or porcine collagen) designed to produce a rapid haemostasis through platelet activation/aggregation (which initiates the haemostatic cascade leading to a fibrin clot) during a surgical procedure. It is applied directly to the wound where it remains to be absorbed by the body; it is not dedicated to a specific anatomy/application and does not contain an antimicrobial agent. It may be supplied as a fibrillar or soft, pliable pad/sponge or loose fibres; it may be applied in combination with fibrin adhesives. This is a single-use device.
Manufacturer
C.R. Bard (a part of BD - Becton, Dickinson and Company) was a global leader in the development and manufacturing of innovative medical technologies. Known for their high-quality products, Bard specialized in solutions for vascular access, urology, oncology, and surgical specialties. Their product portfolio included catheters, biopsy devices, implantable ports, and hernia repair systems, designed to enhance patient care and procedural efficiency. As part of BD, the legacy of C.R. Bard continues to drive advancements in healthcare, delivering trusted solutions that improve outcomes for patients and providers worldwide.
